Jaroslaw Pecold
Research Subjects
Research Interests
Jaroslaw Pecold has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adam Smereka
Department of Gastroenterology and Hepatology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
1 shared publication - Ewa Mańka
Sergeant Grzegorz Załoga Hospital of the Ministry of the Interior and Administration in Katowice , Poland
1 shared publication - Jerzy Robert Ładny
Department of Emergency Medicine, Medical University of Bialystok, 15-089 Bialystok, Poland
1 shared publication - Lukasz Szarpak
Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland
1 shared publication - Maciej Krupowies
Research Unit, Polish Society of Disaster Medicine, 05-806 Warsaw, Poland
1 shared publication - Mahdi Al-Jeabory
Department of Trauma and Orthopedic Surgery, Ruda Slaska City Hospital, 41-703 Ruda Slaska, Poland
1 shared publication
Latest Publications
- Open Access
- 23 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 48
Tranexamic Acid for Shoulder Arthroplasty: A Systematic Review and Meta-Analysis
Tranexamic acid (TXA) is an antifibrinolytic agent that has been shown to decrease blood loss and transfusion rates after knee and hip arthroplasty, however with only limited evidence to support its use in shoulder arthroplasty. Therefore, we performed a systematic review and meta-analysis to evaluate the clinical usefulness of tranexamic acid for shoulder arthroplasty. A thorough literature search was conducted across four electronic databases (PubMed, Cochrane Library, Web of Science, Scopus) from inception through to 1 December 2021. The mean difference (MD), odds ratio (OR) or relative risk (RR) and 95% confidence interval (CI) were used to estimate pooled results from studies. Total of 10 studies comprising of 993 patients met the inclusion criteria and were included in the analysis. Blood volume loss in the TXA and non-TXA group was 0.66 ± 0.52 vs. 0.834 ± 0.592 L (MD= −0.15; 95%CI: −0.23 to −0.07; p < 0.001). Change of hemoglobin levels were 2.2 ± 1.0 for TXA group compared to 2.7 ± 1.1 for non-TXA group (MD= −0.51; 95%CI: −0.57 to −0.44; p < 0.001) and hematocrit change was 6.1 ± 2.7% vs. 7.9 ± 3.1%, respectively; (MD= −1.43; 95%CI: −2.27 to −0.59; p < 0.001). Tranexamic acid use for shoulder arthroplasty reduces blood volume loss during and after surgery and reduces drain output and hematocrit change.
- 23 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 48
Open AccessTranexamic Acid for Shoulder Arthroplasty: A Systematic Review and Meta-Analysis
Tranexamic acid (TXA) is an antifibrinolytic agent that has been shown to decrease blood loss and transfusion rates after knee and hip arthroplasty, however with only limited evidence to support its use in shoulder arthroplasty. Therefore, we performed a systematic review and meta-analysis to evaluate the clinical usefulness of tranexamic acid for shoulder arthroplasty. A thorough literature search was conducted across four electronic databases (PubMed, Cochrane Library, Web of Science, Scopus) from inception through to 1 December 2021. The mean difference (MD), odds ratio (OR) or relative risk (RR) and 95% confidence interval (CI) were used to estimate pooled results from studies. Total of 10 studies comprising of 993 patients met the inclusion criteria and were included in the analysis. Blood volume loss in the TXA and non-TXA group was 0.66 ± 0.52 vs. 0.834 ± 0.592 L (MD= −0.15; 95%CI: −0.23 to −0.07; p < 0.001). Change of hemoglobin levels were 2.2 ± 1.0 for TXA group compared to 2.7 ± 1.1 for non-TXA group (MD= −0.51; 95%CI: −0.57 to −0.44; p < 0.001) and hematocrit change was 6.1 ± 2.7% vs. 7.9 ± 3.1%, respectively; (MD= −1.43; 95%CI: −2.27 to −0.59; p < 0.001). Tranexamic acid use for shoulder arthroplasty reduces blood volume loss during and after surgery and reduces drain output and hematocrit change.